Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load

Iloeje, Uchenna H.; Yang, Hwai I.; Su, Jun; Jen, C.-L.; You, San–Lin; Chen, Chien‐Jen

doi:10.1053/j.gastro.2005.11.016

Cited by 1,401 publications

(1,095 citation statements)

References 39 publications

Supporting

Mentioning

1,031

Contrasting

Unclassified

Order By: Relevance

“…Achieving and maintaining HBV DNA suppression is a principal goal of CHB therapy [25,39]. Data from prospective long-term studies have shown that elevated HBV DNA levels are associated with the development of longterm complications including cirrhosis and HCC [12][13][14]. Other research has correlated durable HBV DNA suppression with improved liver histology among antiviraltreated patients [19,40].…”

Section: Discussionmentioning

confidence: 99%

“…Genotype C virus has been associated with high rates of progression to the complications of CHB, including cirrhosis and HCC [7][8][9][10][11]. In addition to genotype, the level of HBV DNA in the serum is strongly associated with liver disease progression [12,13]. Persistently detectable and elevated viral loads predict the highest risk of progression to cirrhosis and HCC [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

“…In addition to genotype, the level of HBV DNA in the serum is strongly associated with liver disease progression [12,13]. Persistently detectable and elevated viral loads predict the highest risk of progression to cirrhosis and HCC [12][13][14]. Suppression of HBV replication with antiviral therapy may reduce the risk of complications and improve the long-term outcomes of CHB patients [15].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B

et al. 2010

View full text Add to dashboard Cite

Purpose Lamivudine treatment of chronic hepatitis B (CHB) is associated with frequent resistance and loss of clinical benefit. We present outcomes of lamivudinerefractory Japanese patients treated with entecavir for 3 years. Methods Eighty-two patients refractory to lamivudine therapy received entecavir 0.5 or 1 mg daily for 52 weeks in phase II study ETV-052, directly entered rollover study ETV-060, and received entecavir 1 mg daily. Responses were evaluated among patients with available samples.Results After 96 weeks in ETV-060 (148 weeks total entecavir treatment time), 55% (36/65) of patients had hepatitis B virus (HBV) DNA of [400 copies/mL, 85% (52/61) had alanine aminotransferase (ALT) of C1 9 upper limit of normal (ULN), and 14.6% (7/48) achieved HBe seroconversion. A subset of 42 patients received entecavir 1 mg from phase II baseline through 148 weeks: 54% (19/35) had HBV DNA of [400 copies/mL, 84% (27/32) had ALT of C1 9 ULN, and 15% (4/27) achieved HBe seroconversion. Sixteen patients in the 1-mg subset had baseline and week 148 evaluable biopsy pairs: 81% (13/16) showed histologic improvement and 38% (6/16) showed 123Hepatol Int (2010) 4:414-422 DOI 10.1007/s12072-009-9162-x improvement in fibrosis. Genotypic resistance to entecavir emerged in 31 patients for a 3-year cumulative resistance probability of 35.9%. Entecavir was generally well tolerated during ETV-060, with no on-treatment ALT flares. Conclusions Long-term entecavir treatment of lamivudine-refractory CHB resulted in virologic suppression, ALT normalization, and improvements in liver histology. Resistance was consistent with that observed in worldwide studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B

et al. 2010

View full text Add to dashboard Cite

show abstract

“…2,3 The current gold standard in monitoring viral loads is real-time polymerase chain reaction (PCR), which offers high sensitivity and accuracy. 4 Data from these assays reflect the disease status and are employed by most clinical studies.…”

mentioning

confidence: 99%

“…4 Data from these assays reflect the disease status and are employed by most clinical studies. 2,3 The shortcomings of PCR, however, are its relatively high cost and unavailability in some areas. Moreover, viral activity can still be monitored in patients with undetectable HBV DNA through the measurement of hepatitis B surface antigen (HBsAg) and/or hepatitis B e antigen (HBeAg) titers.…”

mentioning

confidence: 99%

Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir

et al. 2011

View full text Add to dashboard Cite

Quantitative hepatitis B surface antigen (qHBsAg) and quantitative hepatitis B e antigen (qHBeAg) titers are emerging as useful tools for measuring viral loads and for predicting the virological response (VR) and serological response (SR) to pegylated interferon therapy. However, the clinical utility of these assays in patients taking entecavir (ETV) is largely unknown. Treatment-naive patients with chronic hepatitis B (CHB) who were taking ETV for 2 years were enrolled. The qHBsAg and qHBeAg levels were serially measured with the Architect assay. From 95 patients, 60.0% of whom were hepatitis B e antigen-positive [HBeAg(1)], 475 samples were analyzed. The median baseline log hepatitis B virus (HBV) DNA, log qHBsAg, and log qHBeAg values were 6.73 copies/mL (4.04-9.11 copies/mL), 3.58 IU/mL (1.17-5.10 IU/ mL), and 1.71 Paul Ehrlich (PE) IU/mL (20.64 to 2.63 PE IU/mL), respectively. For the prediction of VR (HBV DNA < 60 copies/mL at 24 months) in HBeAg(1) patients, baseline alanine aminotransferase (P 5 0.013), HBV DNA (P 5 0.040), and qHBsAg levels (P 5 0.033) were significant. For the prediction of VR, the area under the curve for the baseline log qHBsAg level was 0.823 (P < 0.001); a cutoff level of 3.98 IU/mL (9550 IU/mL on a nonlogarithmic scale) yielded the highest predictive value with a sensitivity of 86.8% and a specificity of 78.9%. As for SR (HBeAg loss at 24 months), the reduction of qHBeAg was significantly greater in the SR(1) group versus the SR(2) group. The sensitivity and specificity were 75.0% and 89.8%, respectively, with a decline of 1.00 PE IU/mL at 6 months. With ETV therapy, the correlation between HBV DNA and qHBsAg peaked at 6 months in HBeAg(1) patients. Conclusion: Both qHBsAg and qHBeAg decreased significantly with ETV therapy. The baseline qHBsAg levels and the on-treatment decline of qHBeAg in HBeAg(1) patients were proven to be highly useful in predicting VR and SR, respectively. The determination of qHBsAg and qHBeAg can help us to select the appropriate strategy for the management of patients with CHB. However, the dynamic interplay between qHBsAg, qHBeAg, and HBV DNA during antiviral therapy remains to be elucidated. (HEPATOLOGY 2011;53:1486-1493 C hronic infection with hepatitis B virus (HBV) is a worldwide health problem, with more than 400 million people thought to be infected.Moreover, these patients are at increased risk for disease progression to cirrhosis and hepatocellular carcinoma. 1 Large cohort studies have shown that elevated levels of Abbreviations: ALT, alanine aminotransferase; anti-HBs, antibody to hepatitis B surface antigen; AUC, area under the curve; AUROC, area under the receiver operating characteristic

show abstract

Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma

Zhong¹,

Li²,

Wu³

2010

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load

Cited by 1,401 publications

References 39 publications

Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B

Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B

Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir

Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma

Contact Info

Product

Resources

About